ArticleEuropean journal of neurology2025

Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemab.

G Logroscino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.